Clinical Trial Update: Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated denosumab for prolonging bone metastasis-free survival in men with castrate-resistant prostate cancer. The results were posted in Marc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castrate-resistant Prostate Cancer

Drugs mentioned

• Xgeva (denosumab)

Snippet

Sponsor: Amgen | Conditions: Castrate-resistant Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-03-05